Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

UCB Data Shows Comparable Performance of Clones Cultured in ambr and 100L Bioreactors

Published: Thursday, April 11, 2013
Last Updated: Thursday, April 11, 2013
Bookmark and Share
Indicating TAP Biosystems’ micro bioreactor is a realistic scale-down model for cell line selection.

TAP Biosystems has announced that new data presented at a Cell Line Development and Engineering meeting by scientists at major European biopharmaceutical firm, UCB has shown that the micro-scale bioreactor system (ambr™) is equivalent in performance to a 100L bioreactor.

This indicates that ambr is a realistic scale-down model and can be used to improve cell line selection processes.

Scientists at UCB used the ambr system to culture five different protein expressing CHO cell lines. One of the five cell lines was also cultured under identical process conditions in 100L Applikon stirred tank bioreactors.

Their results showed that cultures grown in ambr were comparable to those grown in a 100L bioreactor in terms of growth, productivity and protein product quality.

The UCB scientists concluded that using ambr it was possible to test 24 clones in parallel, with results representative of the larger scale. This enables more cell lines to be evaluated in a shorter time, thus increasing the likelihood of selecting higher yielding clones.

Dr Barney Zoro, ambr Product Manager at TAP Biosystems concluded: “The data from UCB is very exciting because it shows that the 15mL ambr micro bioreactor is equivalent in performance to 100L bioreactors, allowing UCB’s scientists to reduce time lines for the cell line selection workflow, with confidence in scalability of the results. So it is now possible and time efficient, to evaluate many more lines for clone selection and this study confirms that using ambr as a scale-down model will provide scientists with a significant benefit when developing antibody and other protein based therapeutics.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck and TAP Biosystems Finalists for “Best Collaboration Award”
Recognizing ambr250 as a breakthrough technology for process development.
Wednesday, October 08, 2014
TAP and Gallus Co-host Free Webinar
Explaining the benefits of using ambr15 microbioreactors for DoE.
Wednesday, October 01, 2014
New Webinars Explore Feed Strategy Challenges Using Mini Bioreactors
Detailing how to achieve consistent feeding regimes for reproducible scale-up.
Thursday, September 25, 2014
New Webinar on Mimicking Perfusion Culture Using Micro Bioreactors
Presents validation data for improving media screening and process optimization.
Friday, February 14, 2014
Scientific News
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!